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ABSTRACT
Leprosy may present kidney and endothelial abnormalities, being a risk factor for 
complications. However, the involvement of renal and vascular endothelia has been poorly 
investigated. We aimed to investigate if the levels of systemic endothelial biomarkers are 
associated with kidney abnormalities and the clinical forms of leprosy. This is a cross-sectional 
study with leprosy patients enrolled in January 2017 to December 2018, before the initiation 
of the multidrug therapy. Leprosy-associated clinical and epidemiological data were collected. 
Two groups were investigated: Paucibacillary (PB) and Multibacillary (MB) infections, for 
the comparisons. Serum and urine samples were obtained for laboratory analysis. In serum 
samples, were evaluated the endothelial biomarkers VCAM-1 and ICAM-1. In total, 101 
leprosy patients were included, the mean age was 48±15 years and 71 (70%) were male. 
The multibacillary form occurred in 81 cases (80%), among which 22 had the Virchowian 
form. Serum creatinine was more elevated in the MB group than in PB patients. In addition, 
VCAM-1 was elevated in the MB group and was correlated with the bacteriological index 
(rho = 0.372, p <0.01), the duration of disease symptoms (rho = 0.234, p = 0.04), and the 
number of skin lesions (rho = 0.468, p <0.001). Moreover, in MB patients who presented 
albuminuria >15 mg/g of creatinine, VCAM-1 showed a significant correlation with 
increased albuminuria and improved the correlation with the number of skin lesions (rho= 
0.563, p=0.010). In conclusion, higher systemic VCAM-1 levels were associated with the 
multibacillary clinical form of leprosy and with increased albuminuria. Prospective studies 
are necessary to establish a cause-effect and evaluate the preventive role of these biomarkers 
to improve the clinical care.
KEYWORDS: Leprosy. Endothelium. Kidney disease. Albuminuria. Paucibacillary leprosy. 
Multibacillary leprosy. 
INTRODUCTION
Leprosy is a millennial disease and also an important neglected disease. 
Despite a major progress in its care and treatment, the global incidence of leprosy 
remains high and is frequently associated with clinical complications in the long 
term1. After the implementation of multidrug therapy, clinical manifestations 
of leprosy have been controlled, including secondary alterations such as renal 
abnormalities2.
However, patients with multibacillary leprosy are at high risk of developing 
kidney disease according to kidney injury scores3. Subclinical renal parameters such 
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as albuminuria and urinary MCP-1levels were previously 
correlated with clinical aspects of the multibacillary form 
of leprosy, including a higher bacteriological index in skin 
smears3.
It is not fully understood if in the long term, even after 
the specific treatment, leprosy patients would have a higher 
incidence of chronic diseases like chronic kidney disease 
(CKD) and hypertension. Nevertheless, investigations on 
subclinical alterations and incipient renal damage during 
leprosy patients care have not been evaluated4. In addition, it 
is not clear if leprosy patients that suffer from other previous 
chronic diseases, like diabetes and hypertension, have a 
higher risk for renal diseases and other complications5. 
Endothelial biomarkers have been associated with 
renal dysfunctions, representing an important tool for 
the early diagnose of renal diseases in various clinical 
contexts6,7. VCAM-1 and ICAM-1 are important molecules 
in the mediation of immunological responses against 
Mycobacterium leprae8. Multiple studies evaluated the 
systemic levels of these endothelial molecules in various 
clinical forms of leprosy8. However, the relationship 
between these levels and important renal parameters has 
not yet been investigated in leprosy patients. 
Thus, the present study aims to seek the association of 
endothelial biomarkers with kidney injury parameters and 
provide important data regarding vascular and renal changes 
in leprosy patients. 
MATERIALS AND METHODS 
Ethical aspects 
The study protocol was reviewed and approved by 
the Ethics Committee of the Federal University of Ceara 
(CAAE Nº 63841417.3.0000.5054), and all the participants 
gave their written informed consent prior to the study 
enrolment.
Study design 
This is a cross-sectional study with leprosy patients. 
Patients were evaluated in Dona Libania Dermatology 
Reference Center, in downtown Fortaleza, Ceara State, 
Brazil, from January 2017 to December 2018.
Leprosy patients of both genders, with ages between 
18 and 60 years old, without kidney diseases, presenting 
with paucibacillary or multibacillary forms of leprosy 
(according to the operational classification of the World 
Health Organization - WHO) were invited to participate in 
this study before the beginning of the multidrug therapy. 
Leprosy patients with reactional episodes were excluded.
Diagnosis and clinical aspects of leprosy
The leprosy diagnosis was based on clinical 
characteristics with the following cardinal signs9: 
a) Hypopigmented or erythematous macules or plaques with 
sensitivity loss; b) Involvement of peripheral nerves, with 
or without thickening, associated with sensitive or motor 
alterations; c) identification of alcohol-acid resistant bacilli 
(BAAR) in skin smears or in biopsies. 
Depending on the number of lesions, WHO has classified 
leprosy into paucibacillary and multibacillary disease. 
Multibacillary disease is considered when the affected 
individual has > 5 skin lesions or > 1 nerve involvement or 
a positive skin smear in any site. The paucibacillary form 
is diagnosed if there are fewer skin lesions or no nerve 
involvement, or if there is only one nerve involvement 
with negative skin smears in all sites. This classification 
is useful from a therapeutic perspective, as paucibacillary 
cases are treated for 6 months, while multibacillary cases for 
12 months using the same treatment regimens (rifampicin, 
dapsone and clofazimine)10. Moreover, the time of disease 
was evaluated according to questionnaires containing the 
patients’ subjective answers, according to their perception 
of the first symptom.
Collection and processing of the biological samples
Venous blood and urine samples were collected. The 
urine samples were collected in a sterile collector cup. 
Urine samples were centrifuged during 15 min 1,000 g for 
the removal of urinary sediments and debris. The urinary 
supernatant was aliquoted and immediately frozen at –80 ºC 
until analysis.
Venous blood samples were collected in appropriate 
tubes for serum isolation. After 15 min, the blood was 
centrifuged, aliquoted and frozen at –80 ºC until analysis. 
Laboratorial analysis
The following parameters were evaluated in urine 
samples: creatinine (Cobas C111, Roche®), proteinuria 
(Labtest®) and glycosuria (Cobas C111, Roche®) through 
enzymatic colorimetric methods; and albuminuria by 
an immunoturbidimetry assay (Cobas C111, Roche®). 
Albuminuria levels over 30 mg/g-Cr may characterize 
a renal alteration11. All the urinary clinical markers 
evaluated had their values adjusted by the urinary creatinine 
values, eliminating the bias of the differences in urinary 
concentrations among patients’ samples12.
Endothelial biomarkers were quantified in the serum 
samples through an immunoenzyme assay (ELISA). Specific 
Rev Inst Med Trop São Paulo. 2021;63:e44
Endothelial activation is associated with albuminuria in multibacillary leprosy
Page 3 of 7
test kits were acquired for VCAM-1 (ab47355, Abcam) 
and ICAM-1 (ab47349, Abcam) and the manufacturer 
instructions were followed. 
Statistical analysis
Categorical data were expressed as absolute counts, and 
frequencies in percentages. Frequencies were compared 
using the Qui-square test. Continuous data were initially 
tested for normal distribution using the Kolmogorov-
Smirnov test and histograms evaluation. Normal or 
almost normal data were reported as mean ± standard 
deviation. Non-normal data were expressed as medians and 
interquartile ranges. The Student t test or the Mann-Whitney 
test were used for comparisons between Paucibacillary and 
Multibacillary groups, according to the distribution of the 
data in each group. Correlations between the endothelial 
biomarkers and renal parameters were evaluated through 
the Spearman correlation (rho de Spearman). The statistical 
analysis used the SPSS program for Macintosh, version 
23.0 (IBM, Armonk, NY, USA). A p<0.05 was considered 
statistical significant for all the analyses.
RESULTS 
Clinical aspects and evaluated groups 
In total, 101 leprosy patients were included before the 
beginning of the specific treatment. There was one or there 
were more signs for the leprosy classification of the patients 
in this study. It was observed that 64 patients had more 
than five skin lesions, 56 patients had positive bacilloscopy 
in skin smears containing lymph, and 16 patients needed 
confirmation by biopsy. From the total of 101 patients, 
20 had the paucibacillary form (PB group) and 81 had the 
multibacillary form (MB group) of leprosy. Into the MB 
group, 22 patients (27%) had the Virchowian clinical form. 
The MB group had significantly more lesions in comparison 
with the PB group (median [IQR]: 10 [6 – 14] vs 1 [1 - 1] 
skin lesions, p<0.001).
The mean age of the leprosy patients was 48±15 years 
and 71 (70%) were male. Only six patients (6%) had 
diabetes and seven (7%) presented cardiac arrhythmias. The 
frequency of diabetes was similar in the PB and the MB 
group (5% vs 6.2% in the MB group, p=0.672) (Table 1).
Albuminuria levels over 30 mg/g-Cr were observed in 
eight patients (8%) (Table 1). Moreover, the patients were 
stratified according to the third quartile (15 mg/g-Cr), 
to uncover a potential more susceptible group and to 
eliminate very low values of albuminuria, a possible bias 
in the correlation analysis. A group of 20 patients with 
albuminuria higher than 15 mg/g-Cr was obtained.
Laboratorial aspects 
Laboratory data were compared between the 
paucibacillary and the multibacillary forms. It was observed 
that only the serum creatinine presented significance 
Table 1 - Clinical aspects evaluated in the studied leprosy patients according to the operational classification.





Gender (Male) 71 (70) 15 (75) 64 (81) 0.946
Age (years) 48 ± 15 47.9 ± 13.37 48.22 ± 15.55 0.934
IMC (kg/m2) 20.1 ± 11.3 22.98 ± 12.29 19.77 ± 10.71 0.249
Diabetes 6 (6) 1 (5) 5 (6.2) 0.672
Arrhythmias 7 (7) 0 (0) 7 (9) 0.514
Albuminuria > 30 mg/g-Cr 8 (8) 0 (0) 8 (10) 0.124
Albuminuria > third quartile# 20 (21) 3 (15) 17 (21) 0.689
Clinical aspects of the disease
Paucibacillary Form 20 (20) - - -
Multibacillary Form 81 (80) - - -
Virchowian form 22 (27) - - -
Number of skin lesions 6 (1 – 14) 1 (1 -1) 10 (6 – 14) <0.001
Bacillary charge 2.48 ± 0.5 - 2.48 ± 0.5 -
Duration of disease (years) 1.6 ± 0.6 1.62 ± 0.72 1.59 ± 0.58 0.828
Quantitative data expressed as mean ± standard deviation for normal data, and as median and interquartile range for non-normal 
data. Categorical data were expressed as absolute counts and percentages between parenthesis; # Quartile 1 = 3.9 / Quartile 2 = 7.1 
and Quartile 3 = 15.0 mg/g-Cr; *Groups were compared using the Student t test for quantitative data. For categorical data, the chi-
square test or the Fisher exact test were used.
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and was higher in the multibacillary patients (Table 2). 
Regarding the endothelial biomarkers, only VCAM-1 was 
elevated in the multibacillary group (Figure 1).
Association between clinical aspects of leprosy with 
VCAM-1 and albuminuria
In the correlation analysis using VCAM-1 and ICAM-1, 
only VCAM-1 presented significant correlations. A 
modest correlation was observed between VCAM-1 and 
the bacteriological index in the skin smears (rho = 0.372, 
p<0.01) and the number of skin lesions (rho = 0.468, 
p<0.001). In addition, VCAM-1 had a weak association 
with the duration of disease symptoms in leprosy patients 
(rho = 0.234, p = 0.04). Importantly, when the patients were 
stratified according to the operational classification, in the 
PB group, no significant correlation between VCAM-1 and 
duration of disease symptoms was observed (rho = 0.101, 
p = 0.72). On the other hand, in the MB group, there was a 
significant correlation among them (rho = 0.272, p = 0.03) 
(Figure 2).
When the correlation between VCAM-1 and albuminuria 
was evaluated in the whole group as well as in the 
multibacillary patients, no significant correlations were 
found. However, due to the large amount of tests showing 
low albuminuria, we decided to evaluate a new group with 
samples presenting higher albuminuria levels, according to 
the third quartile (> 15 mg/g-Cr). In this group VCAM-1 
presented a significant correlation with the albuminuria levels 
(rho = 0.341, p < 0.05). Furthermore, an improvement in the 
correlation between VCAM-1 and the number of skin lesions 
(rho = 0.563, p = 0.010) was also observed (Figure 3). 
DISCUSSION
The main goal of the present study was to investigate 
the levels of endothelial biomarkers and their association 
with albuminuria in multibacillary leprosy. Leprosy can 
affect renal function through different mechanisms, mostly 
immunological, favoring the development of diverse 
clinical complications2. Recently, biomarkers associated 
with endothelial activation, such as VCAM-1, ICAM-1 
and syndecan-1 have been associated with renal diseases in 
multiples clinical contexts such as other infectious diseases 
Table 2 - Laboratory parameters of leprosy patients, according to the clinical form of the disease.
Leprosy patients (n=101) Paucibacillary (n=20) Multibacillary (n=81) p*
Leucocytes 6,756 ± 1,402 7.073 ± 1.528 6.677 ± 1.381 0.455
Platelets (103/mm3) 246.9 ± 85.1 218.8 ± 65.2 253.9 ± 88.8 0.273
Urea (mg/dL) 25.66 ± 8.52 24.86 ± 6.68 26.1 ± 9.0 0.582
Creatinine (mg/dL) 0.75 ± 0.24 0.65 ± 0.23 0.78 ± 0.24 0.030*
Glucose (mg/dL) 109 ± 51.9 111 ± 58.1 108 ± 50.3 0.826
AST (U/L) 26.7 ± 8.9 27.1 ± 11.2 26.6 ± 8.6 0.885
ALT (U/L) 27.5 ± 16.1 31.5 ± 19.1 26.7 ± 15.5 0.420
Albumin (g/dL) 4.0 ± 1.0 4.03 ± 0.8 3.9 ± 0.8 0.362
Proteinuria (mg/g-Cr) 99.8 (65 - 151) 88.2 (65 - 122) 103 (65 - 155) 0.513
Albuminuria (mg/g-Cr) 7.1 (3.9 - 15) 6.3 (3.8 – 14.4) 6.8 (3.9 – 17.1) 0.579
ICAM-1 (ng/mL) 611.29 ± 471.26 602 ± 446 623 ± 485 0.871
VCAM-1 (ng/mL) 1,708.81 ± 765.87 1.101 ± 659 1.826 ± 730 <0.001
AST = aspartate transaminase; ALT = alanine transaminase; data expressed as median, an interquartile amplitude between 
parenthesis for nonparametric data, and as average ± standard deviation for data with normal distribution according to Kolmogorov-
Smirnov; *groups were compared using the Student t test for normal data and the Mann-Whitney test for non-normal data.
Figure 1 - Level of VCAM-1 and ICAM-1 in leprosy patients 
accordingly with the clinical form used to choose the specific 
treatment. *p<0,05 between groups in VCAM-1 levels.
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like leptospirosis and AIDS13-16. In the present study, for 
the first time, the endothelial biomarker VCAM-1 was 
associated with clinical aspects of leprosy, and also with 
albuminuria levels, a renal parameter that often increase in 
multibacillary leprosy patients17. 
The endothelial activation in leprosy has not totally 
been elucidated. The expression of VCAM-1 in the 
endothelial cells occurs in a constitutive manner, but may 
be changed by inflammatory stimuli according to different 
cytokines profiles18. The surrounding products of the 
activated endothelium-like VCAM-1 may be detectable 
earlier, becoming a clinically useful parameter, acting as a 
predictive biomarker in systemic infectious diseases. The 
present study shows that levels of VCAM-1 were increased 
in multibacillary leprosy patients (Virchowians or with the 
“dimorphic” form) than in the paucibacillary group.
According to our literature review, this is the first study 
that evaluates systemic levels of VCAM-1 and correlate 
them with clinical parameters of leprosy. A recent study 
showed the expression of endothelial biomarkers in skin 
lesions through the histochemical analysis of biopsies18. 
In that study, augmented levels of ICAM-1 and more 
importantly of VCAM-1 were significantly present in 
patients with the tuberculoid or the paucibacillary form, 
which, in part, contradicting our findings. In the tuberculoid 
form, the patients present an effective immune response, 
with the augmentation of endothelial adhesion cells that 
optimize the arrival of leukocytes to the infection site19. 
However, despite the VCAM-1 role in the surface of active 
endothelial cells, it is not surprising that the soluble forms 
of VCAM-1 can be released from endothelial cells into the 
bloodstream20. Hence, we suggest that, considering that 
multibacillary patients present a higher dissemination of 
the infection and more inflammatory stimuli throughout the 
whole body21, the endothelial activation may be augmented 
and, consequently, more VCAM-1 molecules will be 
potentially released. In fact, in the present study, VCAM-1 
levels in leprosy patients showed a significant correlation 
with the number of skin lesions, with the bacteriological 
index in skin smears and with the duration of the disease. 
All these parameters are associated with the widespread 
inflammatory activation2.
Moreover, in the present study, leprosy patients with 
albuminuria > 15 mg/g-Cr (mostly multibacillary) had 
increased VCAM-1 levels correlated with both, albuminuria 
levels and number of skin lesions. Endothelial dysfunctions 
have been associated with renal disfunction parameters 
in infectious diseases and with renal diseases in other 
clinical contexts7,8,22. Patients with leptospirosis have major 
lesions in the vascular endothelium due to the invasion of 
Leptospira and as a consequence, endothelial biomarkers 
levels were associated with acute kidney injury (AKI)14. In 
patients with CKD, endothelial disfunctions were associated 
Figure 3 - Scatter plot showing the Spearman correlation 
between systemic VCAM-1 and number of skin lesions in leprosy 
group that presented albuminuria > 15mg/g-Creatinine.
Figure 2 - Scatter plot showing the Spearman correlation between systemic VCAM-1 and duration of leprosy symptoms in 
paucibacillary and multibacillary patients.
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with increased proteinuria and serum creatinine, and 
decreased glomerular filtration rates19. Albuminuria and 
histological findings in leprosy patients represent a CKD 
profile2,3. In diabetic patients, it has already been shown 
that systemic VCAM-1 levels were increased in patients 
with albuminuria > 30 mg/day in comparison with the 
normal albuminuria level group23-25. In a previous study of 
our team, the albuminuria was associated with increased 
urinary MCP-1 levels, a biomarker involved in inflammation 
of the renal tissue and glomerular dysfunction25, and also 
with increased bacillary charges3. Hence, we suggest a 
potential use of VCAM-1 as an early biomarker for leprosy 
complications, including kidney disfunctions.
The present study has limitations. Some patients 
had diabetes, which may have contributed to changes in 
endothelial biomarkers in the leprosy patients. However, 
the frequencies of diabetes were similar among PB and 
MB groups, without statistical significance. In addition, 
the present results with a higher baseline level of VCAM-1 
does not necessarily mean ‘activation’ from a baseline state, 
because another biomarkers of activation would be needed 
to support this hypothesis. In addition, the correlation of 
albuminuria with higher VCAM-1 levels does not prove a 
cause-effect relationship regarding nephropathies. Thus, 
further prospective studies are necessary to stablish the 
risk for the onset of kidney diseases and their outcomes. 
CONCLUSION
In conclusion, leprosy patients with multibacillary forms 
had higher systemic VCAM-1 levels which were associated 
with poorer clinical aspects of leprosy and with increased 
albuminuria, an important marker of kidney diseases 
progression. Further prospective studies are necessary 
to establish a cause-effect relationship and evaluate the 
predictive role of these biomarkers. Moreover, VCAM-1 
and albuminuria screening may provide a preventive tool 
of kidney diseases in leprosy patients, aiming to improve 
the clinical care.
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